Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open‐label studies

Summary Ibrutinib is highly active in treating mantle cell lymphoma ( MCL ), an aggressive B‐cell lymphoma. We pooled data from three ibrutinib studies to explore the impact of baseline patient characteristics on treatment response. Patients with relapsed/refractory MCL ( n = 370) treated with ibrutinib had an objective response rate ( ORR ) of 66% (20% complete response; 46% partial response); median duration of response ( DOR ), progression‐free survival ( PFS ) and overall survival ( OS ) were 18·6, 12·8 and 25·0 months, respectively. Univariate analyses showed patients with one versus >one prior line of therapy had longer OS . Multivariate analyses identified that one prior line of therapy affected PFS ; Eastern Cooperative Oncology Group ( ECOG ) performance status, simplified MCL international prognostic index ( sMIPI ) score, bulky disease, and blastoid histology affected OS and PFS . Patients with blastoid versus non‐blastoid histology had similar time to best response, but lower ORR , DOR , PFS and OS . OS and PFS were longer in patients with better sMIPI , patients with ECOG performance status 0–1, non‐bulky disease and non‐blastoid histology. Additionally, the proportion of patients with poor prognostic factors increased with increasing lines of therapy. Together, results suggest that patient outcomes following treatment failure with ibrutinib are related to the natural biological evolution of the disease.